Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
| Brand name | JENTADUETO XR |
| Generic name | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | LINAGLIPTIN, METFORMIN HYDROCHLORIDE |
| Distributed by / for | Cardinal Health Inc. |
| NDC | 0597-0275-33 |
| Full product label | Jentadueto XR (linagliptin and metformin hydrochloride extended-release) Tablets 5 mg/1000 mg 30 tablets Rx only NDC 0597-0275-33 Dist. by: Boehringer Ingleheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877 USA |
| Recalling firm | Cardinal Health Inc. |
| Distribution | FL, GA, SC |
| Quantity | 52 bottles |
| Recall initiated | 2021-03-15 |
| Report date | 2021-06-02 |
| Recall completed | 2024-06-17 |
| Recall number | D-0457-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗